Frequency Therapeutics stock hits 52-week low at $14.96

Published 03/04/2025, 16:14
Frequency Therapeutics stock hits 52-week low at $14.96

In a challenging year for Frequency Therapeutics Inc, the company’s stock has tumbled to $14.96, near its 52-week low of $15.16, representing an 84% decline from its peak of $98. This price point marks a significant downturn for the biotechnology firm, which specializes in harnessing the body’s innate biology to repair and reverse damage caused by a broad range of degenerative diseases. According to InvestingPro analysis, the company maintains a strong liquidity position with a current ratio of 8.79, though it’s currently trading below its Fair Value. Over the past year, Frequency Therapeutics has seen its stock value erode dramatically, with a 1-year return of -77.76%. This stark decrease reflects investor concerns and market conditions that have weighed heavily on the company’s financial performance and outlook, with EBITDA at -$88.34M. While analyst price targets range from $95 to $180, InvestingPro subscribers can access 12 additional key insights about the company’s financial health and growth prospects through the comprehensive Pro Research Report.

In other recent news, Korro Bio, Inc. has reported several significant developments. The company announced the completion of dosing for the first two cohorts in its Phase 1/2 trial of KRRO-110, an investigational treatment for Alpha-1 Antitrypsin Deficiency (AATD), with interim results expected in the latter half of 2025. This progress in clinical trials follows the U.S. FDA granting orphan drug status to KRRO-110, which provides benefits like tax credits and potential market exclusivity. Additionally, H.C. Wainwright reaffirmed its Buy rating for Korro Bio, maintaining a price target of $115 per share, citing optimism about the trial’s progress.

Korro Bio has also made key executive appointments, including the return of Vineet Agarwal as Chief Financial Officer after a medical leave, and the appointment of Oliver Dolan as Principal Accounting Officer. Dolan was awarded stock options as part of his new role. In another strategic move, the company appointed Loïc Vincent, Ph.D., as Chief Scientific Officer, bringing extensive drug development experience to the team. These changes come as Korro Bio continues to focus on its RNA-editing platform, which aims to address genetic diseases with high unmet needs.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.